Ferroptosis Regulator Information
General Information of the Ferroptosis Regulator (ID: REG10142)
Full List of the Ferroptosis Target of This Regulator and Corresponding Disease/Drug Response(s)
ACVR1B
can regulate the following target(s), and cause disease/drug response(s). You can browse detail information of target(s) or disease/drug response(s).
Browse Target
Browse Disease
Nuclear factor erythroid 2-related factor 2 (NFE2L2) [Suppressor; Marker]
In total 1 item(s) under this target | ||||
Experiment 1 Reporting the Ferroptosis Target of This Regulator | [1] | |||
Target for Ferroptosis | Marker/Suppressor | |||
Responsed Disease | Health | ICD-11: N.A. | ||
Pathway Response | Ferroptosis | hsa04216 | ||
Apoptosis | hsa04210 | |||
Necroptosis | hsa04217 | |||
Cell Process | Cell ferroptosis | |||
Cell apoptosis | ||||
Cell necrosis | ||||
In Vitro Model |
HK-2 cells | Normal | Homo sapiens | CVCL_0302 |
Response regulation | The activin receptor-like kinase (ALK) 4/5 ( ACVR1B/TGFBR1), also known as activin-transforming growth factor (TGF) receptor, is involved in stress-induced renal injury. Pharmacological inhibition of ALK4/5 signaling attenuated erastin-induced ferroptosis by hyperactivating Nrf2 signaling in HK-2 cells. | |||
Health [ICD-11: N.A.]
In total 1 item(s) under this disease | ||||
Experiment 1 Reporting the Ferroptosis-centered Disease Response | [1] | |||
Target Regulator | Activin receptor type-1B (ACVR1B) | Protein coding | ||
Pathway Response | Ferroptosis | hsa04216 | ||
Apoptosis | hsa04210 | |||
Necroptosis | hsa04217 | |||
Cell Process | Cell ferroptosis | |||
Cell apoptosis | ||||
Cell necrosis | ||||
In Vitro Model |
HK-2 cells | Normal | Homo sapiens | CVCL_0302 |
Response regulation | The activin receptor-like kinase (ALK) 4/5 ( ACVR1B/TGFBR1), also known as activin-transforming growth factor (TGF) receptor, is involved in stress-induced renal injury. Pharmacological inhibition of ALK4/5 signaling attenuated erastin-induced ferroptosis by hyperactivating Nrf2 signaling in HK-2 cells. | |||